Clinical trials: Salvage Radiotherapy
Prostate Cancer
PET/MRI for Men Being Considered for Radiotherapy for Suspected Prostate Cancer Recurrence Post-Prostatectomy
The PROPS trial is for men being considered for radiotherapy due to the suspicion that their prostate cancer has recurred following the surgical removal of their prostate (prostatectomy).
- Trial name
- PROPS (NCT02131649)
- Testing
- 18F-FCH PET/MRI Scan
- Where
- 10 sites in Australia, Canada and 1 more
- Volunteers
- 99 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
This phase II trial investigates the effect of extremely hypofractionated intensity modulated stereotactic body radiotherapy in treating patients with prostate cancer that has rising prostate specific antigen (PSA) after radical…
- Conditions
- Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Trial name
- EXCALIBUR (NCT04915508)
- Testing
- Hormone Therapy, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer, Prostatectomy
High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy
The goal of this observational study is to learn about the long-term effects of HDR Brachytherapy in men with isolated local relapses after radical prostatectomy.
- Conditions
- Prostate Cancer, Prostatectomy, Local Recurrence of Malignant Tumor of Prostate, Radiotherapy; Complications
- Trial name
- NCT06982469
- Testing
- Brachytherapy
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Prostate Cancer
Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer
There is an increasing number of reports describing the existence of a proportion of prostate cancer patients who present with a reduced number of metastases (<5 lesions) at relapse.
- Trial name
- OLIGOPELVIS (NCT02274779)
- Testing
- ELIGARD
- Where
- 2 sites in France
- Volunteers
- 74 people
- Sponsor
- Institut Cancerologie de l'Ouest
Prostate Cancer
Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA
The aim of this study is to test whether adding chemotherapy/cabazitaxel and hormonal/androgen deprivation therapy before surgical removal of your prostate would improve the outcome of salvage surgery for locally recurrent…
- Trial name
- NCT01531205
- Testing
- Androgen Ablation, Cabazitaxel, Salvage Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer, Oligometastasis
Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients
Metastatic prostate cancer has traditionally been regarded as an incurable dissemination of disease, and treatment is focused on delaying progression rather than eliminating all tumor burden.
- Trial name
- OLIGOPELVIS2 (NCT03630666)
- Testing
- IADT, IADT + radiotherapy
- Where
- 16 sites in France
- Volunteers
- 256 people
- Sponsor
- Institut Cancerologie de l'Ouest
Prostate Cancer
Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)
This Phase II, single arm study evaluates a PSA-response-adapted approach to salvage radiotherapy after radical prostatectomy for prostate cancer.
- Trial name
- (RANGER) (NCT07313241)
- Testing
- Prostate Fossa Radiotherapy, Pelvic nodal Radiotherapy, Androgen Deprivation Therapy (ADT)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Texas Southwestern Medical Center
HepatoCellular Carcinoma
Comparison of SBRTand Repeat TACE for HCC
Comparison of Stereotactic Body Radiation Therapy (SBRT) and repeated transarterial chemoembolization (TACE) for Hepatocellular Carcinoma (HCC)as a Local Salvage Treatment after first incomplete TACE
- Trial name
- STH (NCT03326375)
- Testing
- SBRT
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Gangneung Asan Hospital
Prostate Cancer, Prostate Adenoma
Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Lymph Node Dissection for Localized Intermediate- and High-risk Prostate Cancer With a Briganti Nomogram≥7%
The goal of this clinical trial is to evaluate efficacy and safety of radical prostatectomy (RP) with or without salvage radiotherapy versus RP with extended pelvic lymph node dissection (ePLND) in males who have localized…
- Trial name
- PRESEL (NCT07115992)
- Testing
- RARP±SRT, RARP+ePLND
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Ruijin Hospital
Prostate Cancer
Focal Salvage Brachytherapy Study (FocaSaBra)
The aim of this prospective phase II study is to evaluate the toxicity of salvage partial (focal) prostate brachytherapy in patients after prior radiotherapy (standard teleradiotherapy with / without brachytherapy…
- Trial name
- FocaSaBra (NCT05715502)
- Testing
- brachytherapy
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- The Greater Poland Cancer Centre
High Grade Glioma
Low Dose Radiation Therapy for Glioblastoma Multiforme
To evaluate the safety and effectiveness of low dose rate radiation therapy plus temozolomide. This will be in patients with High Grade Glioma (to only include Anaplastic Astrocytoma or Glioblastoma Multiforme) who have…
- Trial name
- NCT01466686
- Testing
- Low Dose Fractionated Radiation Therapy (LDFRT), Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient
The objective of this study is to evaluate the predictive value of TMPRSS2-ERG gene fusion in patients with prostate cancer treated with radiation and hormonal therapy.
- Trial name
- NCT02588404
- Testing
- LHRH therapy
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Prostate Cancer
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
The purpose of this study is to describe the 2 year progression-free survival in men with recurrent PSA-only disease after prostatectomy receiving combined enzalutamide and standard androgen-deprivation therapy (ADT) with salvage…
- Trial name
- STREAM (NCT02057939)
- Testing
- enzalutamide, Androgen Deprivation, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Duke University
Hodgkin's Lymphoma
High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients
The purpose of this study is to define an improvement in patients: To evaluate if patients resistant to the initial treatment for residual PET-positive masses after the first two courses of ABVD (PET-2 positive), can be salvaged…
- Trial name
- HD0801 (NCT00784537)
- Testing
- ABVD, ABVD and Radiotherapy
- Where
- 27 sites in Italy
- Volunteers
- 520 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Prostate Cancer
Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy for Prostate Cancer
This is a Phase II prospective single-arm trial that is recruiting 80 participants from patients that have biochemical failure after radical prostatectomy with local or regional recurrence proven by PSMA PET.
- Trial name
- MIDAS-Prostate (NCT05328505)
- Testing
- Image-guided Radiotherapy
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer Adenocarcinoma, Adjuvant Radiotherapy
Stereotactic Hypofractionated Accelerated Radiotherapy Post-Prostatectomy
The present phase I trial evaluates the feasibility of a postoperative stereotactic hypofractionated external beam radiation therapy delivered in patients who underwent radical prostatectomy with adverse pathological features or…
- Conditions
- Prostate Cancer Adenocarcinoma, Adjuvant Radiotherapy, Salvage Radiotherapy, SBRT
- Trial name
- SHARP (NCT02976402)
- Testing
- SBRT
- Where
- Portugal
- Volunteers
- 30 people
- Sponsor
- Fundacao Champalimaud
Prostate Cancer
Urodynamic Evaluation in Post-radiation Salvage Prostatectomy Patients
Objectives: The primary objective of this study is to determine whether bladder compliance is significantly lower in men who undergo prostatectomy for recurrence following primary radiation therapy than in men who undergo…
- Trial name
- NCT00901420
- Testing
- Urodynamics Test, Questionnaire
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if…
- Trial name
- STEEL (NCT03809000)
- Testing
- Radiation Therapy, Enzalutamide, Bicalutamide
- Where
- 108 sites in United States, Canada
- Volunteers
- 188 people
- Sponsor
- RTOG Foundation, Inc.
Prostate Cancer
Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy
The main purpose of this study is to try to find out whether adding chemotherapy to the standard treatment for your stage of prostate cancer is more effective than the standard treatment by itself.
- Trial name
- NCT00480857
- Testing
- Docetaxel (Taxotere)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer
The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy
The objective of the study is to evaluate the predictive value of TMPRSS2-ERG gene fusion and PTEN in patients with high risk prostate cancer treated with first line LHRH agonist after biochemical failure.
- Trial name
- NCT02573636
- Where
- 9 sites in Canada
- Volunteers
- 208 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital